Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride

被引:57
作者
Whitson, Jess T. [1 ]
Cavanagh, H. Dwight [1 ]
Lakshman, Neema [1 ]
Petroll, W. Matthew [1 ]
机构
[1] Univ Texas, SW Med Ctr, Dept Ophthalmol, Dallas, TX 75390 USA
关键词
glaucoma; cornea; benzalkonium chloride; preservative;
D O I
10.1007/BF02850305
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The corneal toxicity of 2 intraocular pressure-lowering agents was compared in a rabbit cornea model with New Zealand White rabbits. Corneal epithelial morphology and cell size were assessed by in vivo confocal microscopy. Baseline microscopic examinations were performed on 1 eye of each animal. Two weeks later, the eyes were bathed for 3 min in travoprost 0.004% preserved without benzalkonium chloride (BAK) or latanoprost 0.005% preserved with 0.02% BAK; the eyes were then rinsed with balanced salt solution, and the corneas were again examined by confocal microscopy (n=4/group). A second group of animals was exposed to the medications through a dosing regimen of 1 drop/min (3 drops total) (n=4/group). in eyes treated with travoprost without BAK (3-min bath), superficial epithelial cells were similar to baseline, as indicated by their visible cell borders and bright nuclei. In contrast, the surface cells in eyes treated with latanoprost were significantly smaller and brighter and had less distinct borders. Surface cell size was significantly smaller as compared with baseline size and as compared with rabbits treated with travoprost without BAK for 3 min. Similar effects on corneal epithelial cell morphology were observed with the 1-drop/min dosing regimen. in this rabbit model, travoprost 0.004% preserved without BAK did not cause corneal epithelial toxicity; latanoprost 0.005% induced superficial cell loss, most likely caused by the presence of a relatively high concentration of BAK (0.02%).
引用
收藏
页码:663 / 671
页数:9
相关论文
共 20 条
  • [11] ICHIJIMA H, 1992, CORNEA, V11, P221
  • [12] JEAN MD, 2000, CURR EYE RES, V20, P85
  • [13] Kovoor Timmy A, 2004, Eye Contact Lens, V30, P90, DOI 10.1097/01.ICL.00000117255.97190.98
  • [14] EFFECT OF TIMOLOL WITH AND WITHOUT PRESERVATIVE ON THE BASAL TEAR TURNOVER IN GLAUCOMA
    KUPPENS, EVMJ
    DEJONG, CA
    STOLWIJK, TR
    DEKEIZER, RJW
    VANBEST, JA
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1995, 79 (04) : 339 - 342
  • [15] Glaucoma and its treatment: A review
    Lee, DA
    Higginbotham, EJ
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (07) : 691 - 699
  • [16] A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma
    Lee, PP
    Walt, JG
    Doyle, JJ
    Kotak, SV
    Evans, SJ
    Budenz, DL
    Chen, PP
    Coleman, AL
    Feldman, RM
    Jampel, HD
    Katz, LJ
    Mills, RP
    Myers, JS
    Noecker, RJ
    Piltz-Seymour, JR
    Ritch, RR
    Schacknow, PN
    Serle, JB
    Trick, GL
    [J]. ARCHIVES OF OPHTHALMOLOGY, 2006, 124 (01) : 12 - 19
  • [17] Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials
    Maier, PC
    Funk, J
    Schwarzer, G
    Antes, G
    Falck-Ytter, YT
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2005, 331 (7509): : 134 - 136B
  • [18] Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study
    Pisella, PJ
    Debbasch, C
    Hamard, P
    Creuzot-Garcher, C
    Rat, P
    Brignole, F
    Baudouin, C
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2004, 45 (05) : 1360 - 1368
  • [19] The number of people with glaucoma worldwide in 2010 and 2020
    Quigley, HA
    Broman, AT
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (03) : 262 - 267
  • [20] Singh Annapurna, 2005, Ophthalmol Clin North Am, V18, P397, DOI 10.1016/j.ohc.2005.05.001